[Comparison of the effects of fenticonazole and econazole on the aspartic proteinase secreted by Candida albicans].
In this note, the effect of fenticonazole on secretory aspartic proteinase of the human opportunistic fungus Candida albicans is shown, in a comparison with econazole. Both antigenic and enzymatic assays demonstrate that fenticonazole, in contrast to econazole, greatly reduces the production of the virulence enzyme by stationary-phase C. albicans. This inhibitory effect was specific and was not mediated by the inhibition of fungal growth. These results confirm fenticonazole's unique property, already shown in previous studies.
De Bernardis
F
F
Laboratoire de Bactériologie et de Mycologie Médicale, Institut Supérieur de la Santé, Rome, Italie.
Cassone
A
A
D000935:Antifungal Agents / Q000494:pharmacology*; D016282:Aspartic Acid Endopeptidases / Q000187:drug effects* / Q000378:metabolism*; D002176:Candida albicans / Q000201:enzymology*; D004353:Drug Evaluation, Preclinical; D004464:Econazole / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*
D000935:Antifungal Agents; D007093:Imidazoles; D004464:Econazole; D016282:Aspartic Acid Endopeptidases; C033486:fenticonazole